Polaryx Therapeutics Jumps 66% on Phase 2 Trial Expansion Plans

The selection of a contract research organization (CRO) marks a pivotal step in the company’s strategy to streamline the clinical development of its pipeline. By targeting multiple conditions simultaneously, the firm aims to utilize what it describes as a resource-efficient mechanism for drug testing. This multi-indication approach follows a safe to proceed letter issued by the U.S. Food and Drug Administration in October 2025, clearing the path for human trials.

Management expects to initiate the Phase 2 study during the first half of 2026. The trial is designed to assess the clinical activity of PLX-200, a compound specifically engineered to address the underlying mechanisms of rare genetic metabolic diseases.

Market Performance and Volatility

Polaryx began trading on the Nasdaq Capital Market on Feb. 2, experiencing significant price fluctuations since its debut. While the stock hit an intraday high of $48.91 during its first session, it has faced downward pressure in recent months before today’s double-digit recovery.